In contrast, the MetS/E + EX group, which includes the SIRT1 inhibitor EX527, showed insignificant reductions in ALT, AST, ALP, and γGT levels compared to the MetS group (p = 0.99, 0.06, 0.76, and 0.99, respectively). The gene discussed is GPT; the disease is metabolic syndrome.